Locally advanced NSCLC: current state of the art, treatment and future directions.

Hak Choy, Philip D. Bonomi

Research output: Contribution to journalArticle

Abstract

Combined chemoradiotherapy is the current treatment standard for patients with locally advanced non-small cell lung cancer. Recent trials have shown increased benefit with concurrent versus sequential administration. Specifically, recently reported results of a large, randomized phase II trial support this conclusion and provide evidence that the addition of consolidation chemotherapy after concurrent chemoradiotherapy may further improve outcome. Concurrent chemoradiotherapy offers substantially improved 2-year survival among patients with locally advanced disease over the previous standards of radiotherapy alone and sequential administration of chemotherapy and radiotherapy. To further improve survival, investigators are evaluating the addition of molecularly targeted therapy to chemoradiotherapy in this treatment setting. The current focus of research is the addition of epidermal growth factor receptor inhibitors (tyrosine kinase inhibitors or monoclonal antibodies), which appear to act synergistically with radiotherapy. Current trials are combining these inhibitors with chemoradiotherapy in a variety of treatment strategies, including induction, primary, consolidation, and maintenance therapy. This article reviews the development of the current treatment standard and current research into new treatments with epidermal growth factor receptor inhibitors.

Original languageEnglish (US)
JournalJournal of the National Comprehensive Cancer Network : JNCCN
Volume2 Suppl 2
StatePublished - Sep 2004

Fingerprint

Chemoradiotherapy
Radiotherapy
Epidermal Growth Factor Receptor
Therapeutics
Consolidation Chemotherapy
Survival
Direction compound
Research
Non-Small Cell Lung Carcinoma
Protein-Tyrosine Kinases
Monoclonal Antibodies
Research Personnel
Drug Therapy

ASJC Scopus subject areas

  • Oncology

Cite this

Locally advanced NSCLC : current state of the art, treatment and future directions. / Choy, Hak; Bonomi, Philip D.

In: Journal of the National Comprehensive Cancer Network : JNCCN, Vol. 2 Suppl 2, 09.2004.

Research output: Contribution to journalArticle

@article{fea1ace85896458bb52aeec9ade95b6c,
title = "Locally advanced NSCLC: current state of the art, treatment and future directions.",
abstract = "Combined chemoradiotherapy is the current treatment standard for patients with locally advanced non-small cell lung cancer. Recent trials have shown increased benefit with concurrent versus sequential administration. Specifically, recently reported results of a large, randomized phase II trial support this conclusion and provide evidence that the addition of consolidation chemotherapy after concurrent chemoradiotherapy may further improve outcome. Concurrent chemoradiotherapy offers substantially improved 2-year survival among patients with locally advanced disease over the previous standards of radiotherapy alone and sequential administration of chemotherapy and radiotherapy. To further improve survival, investigators are evaluating the addition of molecularly targeted therapy to chemoradiotherapy in this treatment setting. The current focus of research is the addition of epidermal growth factor receptor inhibitors (tyrosine kinase inhibitors or monoclonal antibodies), which appear to act synergistically with radiotherapy. Current trials are combining these inhibitors with chemoradiotherapy in a variety of treatment strategies, including induction, primary, consolidation, and maintenance therapy. This article reviews the development of the current treatment standard and current research into new treatments with epidermal growth factor receptor inhibitors.",
author = "Hak Choy and Bonomi, {Philip D.}",
year = "2004",
month = "9",
language = "English (US)",
volume = "2 Suppl 2",
journal = "Journal of the National Comprehensive Cancer Network : JNCCN",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",

}

TY - JOUR

T1 - Locally advanced NSCLC

T2 - current state of the art, treatment and future directions.

AU - Choy, Hak

AU - Bonomi, Philip D.

PY - 2004/9

Y1 - 2004/9

N2 - Combined chemoradiotherapy is the current treatment standard for patients with locally advanced non-small cell lung cancer. Recent trials have shown increased benefit with concurrent versus sequential administration. Specifically, recently reported results of a large, randomized phase II trial support this conclusion and provide evidence that the addition of consolidation chemotherapy after concurrent chemoradiotherapy may further improve outcome. Concurrent chemoradiotherapy offers substantially improved 2-year survival among patients with locally advanced disease over the previous standards of radiotherapy alone and sequential administration of chemotherapy and radiotherapy. To further improve survival, investigators are evaluating the addition of molecularly targeted therapy to chemoradiotherapy in this treatment setting. The current focus of research is the addition of epidermal growth factor receptor inhibitors (tyrosine kinase inhibitors or monoclonal antibodies), which appear to act synergistically with radiotherapy. Current trials are combining these inhibitors with chemoradiotherapy in a variety of treatment strategies, including induction, primary, consolidation, and maintenance therapy. This article reviews the development of the current treatment standard and current research into new treatments with epidermal growth factor receptor inhibitors.

AB - Combined chemoradiotherapy is the current treatment standard for patients with locally advanced non-small cell lung cancer. Recent trials have shown increased benefit with concurrent versus sequential administration. Specifically, recently reported results of a large, randomized phase II trial support this conclusion and provide evidence that the addition of consolidation chemotherapy after concurrent chemoradiotherapy may further improve outcome. Concurrent chemoradiotherapy offers substantially improved 2-year survival among patients with locally advanced disease over the previous standards of radiotherapy alone and sequential administration of chemotherapy and radiotherapy. To further improve survival, investigators are evaluating the addition of molecularly targeted therapy to chemoradiotherapy in this treatment setting. The current focus of research is the addition of epidermal growth factor receptor inhibitors (tyrosine kinase inhibitors or monoclonal antibodies), which appear to act synergistically with radiotherapy. Current trials are combining these inhibitors with chemoradiotherapy in a variety of treatment strategies, including induction, primary, consolidation, and maintenance therapy. This article reviews the development of the current treatment standard and current research into new treatments with epidermal growth factor receptor inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=73349107483&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73349107483&partnerID=8YFLogxK

M3 - Article

C2 - 19780243

AN - SCOPUS:73349107483

VL - 2 Suppl 2

JO - Journal of the National Comprehensive Cancer Network : JNCCN

JF - Journal of the National Comprehensive Cancer Network : JNCCN

SN - 1540-1405

ER -